Developed nations expanding vaccination recommendations against seasonal influenza and growth of egg-based quadrivalent seasonal influenza vaccines are expected to increase growth of the seasonal influenza vaccine market, says a report by GlobalData.
Titled 'PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025', the report analyses the market for seasonal influenza vaccines across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan.
Go deeper with GlobalData
The market for these vaccines in the 7MM is forecast to grow at a rise compound annual growth rate of 3.3% between 2015 and 2025 to reach $4.3bn in value by the end of the forecast period.
The US and the UK amending their national immunisation schedules, and Germany, Italy, France and Spain expanding recommendations of egg-based quadrivalent vaccines are some of the reasons behind the anticipated growth.
Countries such as Japan have replaced trivalent vaccines with quadrivalent vaccines as the latter cover more influenza types than trivalent vaccines. Quadrivalents are expected to replace trivalent vaccines fully over the next five years in the US, while Europe is also expected to adopt quadrivalent vaccines widely by 2025.
GlobalData’s director of infectious diseases Christopher J Pace, PhD says “More recently, developed countries such as the US and UK have issued expanded recommendations for the vaccination of healthy children and adolescents against seasonal influenza, thereby indirectly protecting high-risk groups such as the elderly and the immunocompromised from disease by disrupting community transmission. This generates a significant new opportunity for market penetration.”
Vaccination rate is expected to remain stable, but use of quadrivalent vaccines, which are priced higher, and other advanced immunisations such as Sanofi’s Fluzone High-Dose and CSL’s Fluad will help the market grow in value, adds Pace.
Furthermore, a transition from egg-based to cell culture-based vaccines is expected to drive market growth. CSL launched Flucelvax, its first quadrivalent cell culture-based vaccine, in the US this year for children older than four.
Cell culture-based vaccines are suitable even for those allergic to egg-based vaccines, giving them a competitive advantage over the latter.
Other significant products anticipated to revitalise the influenza market are novel, virus-like particle vaccines by Novavax and Mitsubishi Tanabe, which are expected to lead to the development of a universal seasonal influenza vaccine.
